Guerbet S. A. - Asset Resilience Ratio
Guerbet S. A. (GBT) has an Asset Resilience Ratio of 3.49% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read GBT liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2004–2024)
This chart shows how Guerbet S. A.'s Asset Resilience Ratio has changed over time. See Guerbet S. A. (GBT) shareholders funds for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Guerbet S. A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Guerbet S. A. (GBT) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €36.17 Million | 3.49% |
| Total Liquid Assets | €36.17 Million | 3.49% |
Asset Resilience Insights
- Limited Liquidity: Guerbet S. A. maintains only 3.49% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Guerbet S. A. Industry Peers by Asset Resilience Ratio
Compare Guerbet S. A.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Demant A/S
CO:DEMANT |
Medical Devices | -2.59% |
|
Double Medical Technology Inc
SHE:002901 |
Medical Devices | 7.79% |
|
Beijing Wandong Medical Technology Co Ltd
SHG:600055 |
Medical Devices | 4.92% |
|
Sinocare Inc
SHE:300298 |
Medical Devices | 3.53% |
|
MODULIGHT OY EO 1
F:78W |
Medical Devices | 22.31% |
|
Diagnostic Medical Systems SA
PA:ALDMS |
Medical Devices | 1.39% |
|
Theradiag SA
PA:ALTHE |
Medical Devices | 15.59% |
|
Nova EYE Medical Ltd
AU:EYE |
Medical Devices | 11.08% |
Annual Asset Resilience Ratio for Guerbet S. A. (2004–2024)
The table below shows the annual Asset Resilience Ratio data for Guerbet S. A..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 3.49% | €36.17 Million ≈ $42.29 Million |
€1.04 Billion ≈ $1.21 Billion |
-0.56pp |
| 2023-12-31 | 4.05% | €41.48 Million ≈ $48.50 Million |
€1.03 Billion ≈ $1.20 Billion |
-0.34pp |
| 2022-12-31 | 4.38% | €41.17 Million ≈ $48.13 Million |
€939.64 Million ≈ $1.10 Billion |
+0.10pp |
| 2021-12-31 | 4.29% | €42.90 Million ≈ $50.15 Million |
€1.00 Billion ≈ $1.17 Billion |
+0.78pp |
| 2020-12-31 | 3.51% | €33.15 Million ≈ $38.76 Million |
€945.71 Million ≈ $1.11 Billion |
-0.07pp |
| 2019-12-31 | 3.57% | €36.04 Million ≈ $42.13 Million |
€1.01 Billion ≈ $1.18 Billion |
-0.89pp |
| 2018-12-31 | 4.46% | €48.22 Million ≈ $56.38 Million |
€1.08 Billion ≈ $1.26 Billion |
-0.48pp |
| 2017-12-31 | 4.94% | €47.09 Million ≈ $55.06 Million |
€953.59 Million ≈ $1.11 Billion |
+4.84pp |
| 2016-12-31 | 0.10% | €1.03 Million ≈ $1.21 Million |
€1.03 Billion ≈ $1.20 Billion |
-0.01pp |
| 2015-12-31 | 0.11% | €975.00K ≈ $1.14 Million |
€902.50 Million ≈ $1.06 Billion |
+0.03pp |
| 2014-12-31 | 0.08% | €361.00K ≈ $422.05K |
€475.63 Million ≈ $556.07 Million |
-0.03pp |
| 2013-12-31 | 0.11% | €494.00K ≈ $577.54K |
€459.55 Million ≈ $537.26 Million |
+0.06pp |
| 2012-12-31 | 0.05% | €239.00K ≈ $279.42K |
€460.97 Million ≈ $538.92 Million |
-7.18pp |
| 2008-12-31 | 7.23% | €27.69 Million ≈ $32.37 Million |
€382.96 Million ≈ $447.72 Million |
+7.29pp |
| 2006-12-31 | -0.06% | €-192.00K ≈ $-224.47K |
€326.51 Million ≈ $381.72 Million |
+0.03pp |
| 2005-12-31 | -0.09% | €-268.00K ≈ $-313.32K |
€295.81 Million ≈ $345.84 Million |
+0.00pp |
| 2004-12-31 | -0.09% | €-235.00K ≈ $-274.74K |
€255.67 Million ≈ $298.91 Million |
-- |
About Guerbet S. A.
Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate solution; Conray, an iothalamate meglumine injection; Micropaque/Microtrast, a diagnostic imaging interconnected solut… Read more